The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

Scientists at IIT Roorkee have achieved a major breakthrough by identifying a potential drug for the treatment of chikungunya ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Named after Indiana teenager Ryan White – who contracted HIV in 1984 after receiving an untested blood transfusion while ...

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

IIT Roorkee researchers have discovered that Efavirenz, an HIV drug, may help treat Chikungunya by reducing virus replication in lab tests and mice models. While promising, clinical trials are needed ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Efavirenz (EFV), brand-named drugs such as Sustiva, is an antiretroviral drug utilized mostly for HIV/AIDS treatment and prevention. Efavirenz is a category of drugs that fall under non-nucleoside ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.